# A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib

> **NCT04959266** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 5 (actual)

## Conditions studied

- Advanced Solid Tumours

## Interventions

- **DRUG:** Adavosertib
- **DRUG:** Itraconazole
- **DRUG:** Rifampicin
- **DRUG:** Omeprazole

## Key facts

- **NCT ID:** NCT04959266
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-28
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-06-01
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** The study terminated because the clinical development programme for Adavosertib has been discontinued
- **Last updated:** 2022-09-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04959266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04959266, "A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04959266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*